Taysha Gene Therapies (TSHA) EPS (Weighted Average and Diluted) (2021 - 2026)
Taysha Gene Therapies' (TSHA) quarterly EPS (Weighted Average and Diluted) came in at -$0.12 in Q1 2026, down 50.0% year-on-year from -$0.24 in Q1 2025, and down 50.0% quarter-over-quarter from -$0.08 in Q4 2025.
Taysha Gene Therapies (TSHA) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Taysha Gene Therapies has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$0.12 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.12, down 50.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.38 (down 11.76% YoY), and the FY2025 annual result was -$0.34, up 5.56% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.12 for Q1 2026 at Taysha Gene Therapies, down from -$0.08 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.92 in Q4 2023 to a low of -$1.32 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.1 (2024), against an average of -$0.31.
- Across the five-year window, EPS (Weighted Average and Diluted) soared 192.93% in 2023 and sank 107.61% in 2024, its largest moves.
- Taysha Gene Therapies' EPS (Weighted Average and Diluted) stood at -$0.99 in 2022, then jumped by 192.93% to $0.92 in 2023, then tumbled by 107.61% to -$0.07 in 2024, then declined by 14.29% to -$0.08 in 2025, then slumped by 50.0% to -$0.12 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.12 (Q1 2026), -$0.08 (Q4 2025), and -$0.09 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.12 |
| Dec 31, 2025 | -0.08 |
| Sep 30, 2025 | -0.09 |
| Jun 30, 2025 | -0.09 |
| Mar 31, 2025 | -0.08 |
| Dec 31, 2024 | -0.07 |
| Sep 30, 2024 | -0.10 |
| Jun 30, 2024 | -0.09 |
| Mar 31, 2024 | -0.10 |
| Dec 31, 2023 | 0.92 |
| Sep 30, 2023 | -0.93 |
| Jun 30, 2023 | -0.38 |
| Mar 31, 2023 | -0.28 |
| Dec 31, 2022 | -0.99 |
| Sep 30, 2022 | -0.65 |
| Jun 30, 2022 | -0.85 |
| Mar 31, 2022 | -1.32 |
| Dec 31, 2021 | -1.33 |
| Sep 30, 2021 | -1.35 |
| Jun 30, 2021 | -1.09 |